Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Highlights ASCO
Conference Highlights ASCO
PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
Play Video
FDA Approvals
,
Conference Highlights ASCO
Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma
Play Video
Conference Highlights ASCO
Precision Medicine and Immunotherapy Highlighted at ASCO 2018
Wayne Kuznar
Play Video
Value-Based Care
,
Conference Highlights ASCO
Rapid Biosimilar Adoption Possible in Community Oncology Practice
Chase Doyle
Chase Doyle
Play Video
FDA Approvals
,
Leukemia
,
Lymphoma
,
Conference Highlights ASCO
Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma
Play Video
Conference Highlights ASCO
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Play Video
Cholangiocarcinoma
,
FDA Approvals
,
Conference Highlights ASCO
Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Play Video
Prostate Cancer
,
Conference Highlights ASCO
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Phoebe Starr
Phoebe Starr
Play Video
1
2
Page 2 of 2
Results 11 - 18 of 18